RT Journal Article
SR Electronic
T1 Drivers and impact of the early silent invasion of SARS-CoV-2 Alpha
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.21.23293488
DO 10.1101/2023.08.21.23293488
A1 Faucher, Benjamin
A1 Sabbatini, Chiara E.
A1 Czuppon, Peter
A1 Kraemer, Moritz U.G.
A1 Lemey, Philippe
A1 Colizza, Vittoria
A1 Blanquart, Francois
A1 Boëlle, Pierre-Yves
A1 Poletto, Chiara
YR 2024
UL http://medrxiv.org/content/early/2024/01/22/2023.08.21.23293488.abstract
AB SARS-CoV-2 variants of concern (VOCs) circulated cryptically before being identified as a threat, delaying interventions. Here we studied the drivers of such silent spread and its epidemic impact to inform future response planning. We focused on Alpha spread out of the UK. We integrated spatio-temporal records of international mobility, local epidemic growth and genomic surveillance into a Bayesian framework to reconstruct the first three months after Alpha emergence. We found that silent circulation lasted from days to months and decreased with the logarithm of sequencing coverage. Social restrictions in some countries likely delayed the establishment of local transmission, mitigating the negative consequences of late detection. Revisiting the initial spread of Alpha supports local mitigation at the destination in case of emerging events.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is partially funded by: the Municipality of Paris through the programme Emergence(s) to C.P. and B.F.; the Agence Nationale de la Recherche project DATA REDUX (ANR 19 CE46 0008 03) to V.C.; ANRS Maladies Infectieuses Emergentes project EMERGEN (ANRS0151) to V.C.; EU Horizon 2020 grants MOOD (H2020 874850) to V.C., C.P., P.Y.B., M.U.G.K., P.L. and RECOVER (H2020- 101003589) to V.C.; the ERC grant EvoComBac 949208 to F.B.; ERC grant ReservoirDOCS 725422 to P.L.; Institut des Sciences du Calcul et de la Donnee (ISCD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe findings of this study are based on metadata associated with a total of 1,735,675 sequences available on GISAID and submitted between 15 Aug 2020 and 1 Jun 2021 included and downloaded on 2 Jun 2021 via gisaid.org (GISAID: EPI_SET_230724tv). To view the contributors of each sequence associated with the metadata we used, visit https://doi.org/10.55876/gis8.230724tv. Proprietary airline data are commercially available from OAG and IATA databases. All other data used in the study are publicly available online at the links provided in the references.